Take­da is beef­ing up its NASH pipeline with a $470M dis­cov­ery deal with He­mo­S­hear

Ten months af­ter ty­ing up with Arc­turus on an RNA pro­gram for NASH, Take­da is back beef­ing up its pipeline for the liv­er dis­ease by turn­ing to the Char­lottesville, VA biotech.

NASH is one of the liv­er dis­eases Take­da and He­mo­S­hear plan to suss out in a $470 mil­lion dis­cov­ery col­lab­o­ra­tion, which in­cludes an up­front and R&D mon­ey as well as a long string of mile­stones for any longterm suc­cess­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.